FDA Strikes Out Amneal Pharmaceuticals' Parkinson's Disease Candidate, Stock Falls
Portfolio Pulse from Vandana Singh
Amneal Pharmaceuticals Inc received an FDA Complete Response Letter (CRL) regarding its New Drug Application for IPX203 for Parkinson's disease. The FDA requested additional information about one of the drug's ingredients, carbidopa. The company's shares fell 13.1% in premarket trading following the news. The company stated that this update does not impact its 2023 financial guidance.
July 05, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amneal Pharmaceuticals' stock price fell following the FDA's request for additional information on its Parkinson's drug. The company maintains that this will not affect its 2023 financial guidance.
The FDA's request for additional information on IPX203 has led to a drop in Amneal's stock price. However, the company has stated that this will not impact its 2023 financial guidance, which may mitigate some investor concerns.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100